Clinical trial
Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial
NCT04851132 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial
- Lead sponsor
- Chinese Academy of Medical Sciences
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- March 11, 2021
- Completion date
- June 30, 2023
- Enrollment
- 33 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.